Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.

Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8292-7. doi: 10.1073/pnas.0707761105. Epub 2008 Jun 10.

2.

Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.

Doepfner KT, Boller D, De Laurentiis A, Guerreiro AS, Marinov M, Arcaro A.

Recent Pat DNA Gene Seq. 2007;1(1):9-23. Review.

PMID:
19075915
3.

Reprint of Neutrophil cell surface receptors and their intracellular signal transduction pathways.

Futosi K, Fodor S, Mócsai A.

Int Immunopharmacol. 2013 Dec;17(4):1185-97. doi: 10.1016/j.intimp.2013.11.010. Epub 2013 Nov 18. Review.

PMID:
24263067
4.

Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions.

Gratacap MP, Guillermet-Guibert J, Martin V, Chicanne G, Tronchère H, Gaits-Iacovoni F, Payrastre B.

Adv Enzyme Regul. 2011;51(1):106-16. doi: 10.1016/j.advenzreg.2010.09.011. Epub 2010 Oct 28. Review.

PMID:
21035500
5.

Should individual PI3 kinase isoforms be targeted in cancer?

Jia S, Roberts TM, Zhao JJ.

Curr Opin Cell Biol. 2009 Apr;21(2):199-208. doi: 10.1016/j.ceb.2008.12.007. Epub 2009 Feb 4. Review.

6.

PI3K class IB pathway.

Andrews S, Stephens LR, Hawkins PT.

Sci STKE. 2007 Oct 9;2007(407):cm2. Review.

7.

The regulation of class IA PI 3-kinases by inter-subunit interactions.

Backer JM.

Curr Top Microbiol Immunol. 2010;346:87-114. doi: 10.1007/82_2010_52. Review.

8.
9.

G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling.

Riaz A, Huang Y, Johansson S.

Int J Mol Sci. 2016 Feb 5;17(2):215. doi: 10.3390/ijms17020215. Review.

10.

p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?

Singh P, Dar MS, Dar MJ.

FEBS Lett. 2016 Sep;590(18):3071-82. doi: 10.1002/1873-3468.12377. Epub 2016 Sep 12. Review.

PMID:
27552098
11.

Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts.

Falasca M, Maffucci T.

Front Physiol. 2014 Oct 15;5:391. doi: 10.3389/fphys.2014.00391. eCollection 2014. Review.

12.

Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase.

Oak JS, Matheu MP, Parker I, Cahalan MD, Fruman DA.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1109-13. Review.

13.

Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders.

Gross C, Bassell GJ.

Front Mol Neurosci. 2014 Feb 13;7:12. doi: 10.3389/fnmol.2014.00012. eCollection 2014. Review.

14.

PI3K class IB pathway in neutrophils.

Andrews S, Stephens LR, Hawkins PT.

Sci STKE. 2007 Oct 9;2007(407):cm3. Review.

15.

Class I PI3K in oncogenic cellular transformation.

Zhao L, Vogt PK.

Oncogene. 2008 Sep 18;27(41):5486-96. doi: 10.1038/onc.2008.244. Review.

16.

Synergy in activating class I PI3Ks.

Burke JE, Williams RL.

Trends Biochem Sci. 2015 Feb;40(2):88-100. doi: 10.1016/j.tibs.2014.12.003. Epub 2015 Jan 5. Review.

PMID:
25573003
17.

Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase.

Dbouk HA, Backer JM.

Trends Pharmacol Sci. 2013 Mar;34(3):149-53. doi: 10.1016/j.tips.2012.12.004. Epub 2013 Feb 12. Review.

18.

A beta version of life: p110β takes center stage.

Dbouk HA, Backer JM.

Oncotarget. 2010 Dec;1(8):729-33. Review.

19.

G protein-coupled receptors go extracellular: RhoA integrates the integrins.

Walsh CT, Stupack D, Brown JH.

Mol Interv. 2008 Aug;8(4):165-73. doi: 10.1124/mi.8.4.8. Review.

20.

Phosphatidylinositol 3-kinase: the oncoprotein.

Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A.

Curr Top Microbiol Immunol. 2010;347:79-104. doi: 10.1007/82_2010_80. Review.

Supplemental Content

Support Center